Tocilizumab (Anti-Human IL6R) is a neutralizing antibody against human interleukin-6 receptor (IL-6R) that blocks the binding of IL-6 to IL-6R, thereby inhibiting both classical and trans signaling. It can be used to study rheumatoid arthritis and has been suggested as a possible drug for the treatment of severe COVID-19.

方法：Tocilizumab （Anti-Human IL6R)（0.001–10,000 μg/ml） 培养 Ba/F3-gp130-hIL-6R 或 Ba/F3-gp130-mIL-6R 细胞 2 天，观察细胞增殖情况。
结果：Tocilizumab （Anti-Human IL6R)可以抑制细胞增殖，IC50值为 13.5 ng/mL。[1]

方法：将HARA-B细胞接种到裸鼠心脏的左心室，接种三周后，在接下来的三周内每周静脉注射Tocilizumab （Anti-Human IL6R)（1.0 mg/100 μL，两周一次，三周） 。
结果：在Tocilizumab （Anti-Human IL6R)注射的小鼠大脑中，每个转移病灶的体积显着较小。[2]

Objective: To validate that IL-6 signaling is essential for TAM (tumor-associated macrophages)-enhanced CSC (cancer stem cells) function. Concentrations: 5 μg/ml. Incubation Time: 72 h. Method: For co-culture experiments, 12-well Transwell chambers were used with 2×105 HepG2 or Hep3B cells seeded in the lower chamber one day before co-culture and either 5×105 or 1×106 TAMs added in the upper chamber. Tocilizumab or human IgG antibody were added in indicated experiments to selected wells. After 24 to 72 hours, HCC cells and CD14+ TAM cells were collected separately for analysis. Cells:HepG2 cell lines, TAMs isolated from HCCs (hepatocellular carcinoma)